Jul 2 |
Lucid Diagnostics Announces Positive Data from its ESOGUARD BE-1 Prospective, International, Multicenter Clinical Validation Study of EsoGuardĀ® Esophageal Precancer Testing in a Screening Population
|
Jun 13 |
PAVmed Subsidiary, Veris Health, Announces Launch of Pilot Program with The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute
|
Jun 12 |
4,000th Firefighter Undergoes Lucid Diagnostics' EsoGuardĀ® Esophageal Precancer Testing
|
May 15 |
PAVmed Inc (PAVM) Q1 2024 Earnings Call Transcript Highlights: Strategic Growth and Financial ...
|
May 15 |
Q1 2024 PAVmed Inc Earnings Call
|
May 14 |
PAVmed Inc. (PAVM) Q1 2024 Earnings Call Transcript
|
May 14 |
PAVmed Non-GAAP EPS of -$0.99 beats by $0.56, revenue of $1.01M misses by $0.03M
|
May 14 |
PAVmed Provides Business Update and First Quarter 2024 Financial Results
|
May 13 |
PAVmed Q1 2024 Earnings Preview
|
May 13 |
Lucid Diagnostics Provides Business Update and First Quarter 2024 Financial Results
|